Adrian Marcelo Duek

Dr. Adrian Marcelo Duek


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2024 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
ADAdrian Marcelo Duek
Adrian Marcelo Duek
ATAlexandra Tzinman
Alexandra Tzinman
KMKira Maziuk
Kira Maziuk
ALAssaf Levy
Assaf Levy
MEMartin Ellis
Martin Ellis
MLMerab Leiba
Merab Leiba
Introduction: In recent years, fedratinib, a selective JAK2 inhibitor, has emerged as a potential therapeutic option for patients who have failed or are intolerant to ruxolitinib. Despite the promising results observed in clinical studies, real-world evidence from the USA and Europe suggests that the efficacy of fedratinib may be less conclusive. We report the characteristics, treatment patterns, and clinical outcomes of patients with myelofibrosis (MF) treated with fedratinib following ruxolitinib failure in Israel’s clinical practice. Methods: This retrospective patient chart review included adults with a physician-reported diagnosis of MF, who initiated fedratinib after discontinuing ruxolitinib. Descriptive analyses characterized patient characteristics, clinical outcomes, and treatment patterns from MF diagnosis through ruxolitinib and fedratinib treatment. Results: We extracted data for 16 eligible patients. Approximately 62.5% of the patients were female, and the median age was 77 (range: 63–85) years. The median duration of ruxolitinib therapy was 17 months (range: 3–84) months. Before the initiation of fedratinib, the median spleen size by palpation was 15.5 cm below the costal margin (range: 4–22 cm). After 3 months the median spleen size was 13 cm below the costal margin (range: 2–21 cm). Only 2 patients showed minimal improvement after 6 months, while 3 patients progressed, and 2 patients showed no change in the spleen size. The spleen response did not improve after 12 months of treatment. At this point, the median spleen size was 19 cm below the costal margin (range: 2–30 cm). Regarding the MF-related symptoms, 43.75% (n = 7) of patients reported some improvement, 37.5% (n = 6) showed no changes, whereas 18.75% (n = 3) of the population complained of worsening. Gastrointestinal toxicity was the most frequent adverse effect of the drug, while 31% of patients died. Conclusion: Our observations showed that in MF patients who have failed to ruxolitinib, the therapeutic value from fedratinib may be modest, especially when exposure time to ruxolitinib was more than 12 months. Early switching from ruxolitinib to fedratinib may yield a better result.

30 November 2025 in Life
Verified
Journal Article
Open access
PDF file
ADAdrian Marcelo Duek
Adrian Marcelo Duek
AZAlexandra Zimin
Alexandra Zimin
YHYael Hershkop
Yael Hershkop
CCCipok Cipok
Cipok Cipok
ACAmir Cohen
Amir Cohen
MLMerav Leiba
Merav Leiba
Although COVID-19 is associated with significant thrombo-inflammatory complications, reliable biomarkers to guide antithrombotic therapy remain limited. Immature platelet fraction (IPF) reflects platelet turnover and may indicate heightened thrombotic risk. We retrospectively analyzed 133 hospitalized COVID-19 patients (median age 68 years) at a single center. IPF and inflammatory markers (WBC, ANC, D-dimer, LDH, CRP) were measured on admission. Correlations between IPF and these biomarkers were assessed overall and in clinical subgroups (age, sex, disease severity, comorbidities, and treatment). We found that IPF was positively correlated with WBC and ANC in patients less than 70 years old (r = 0.36 and 0.33, respectively; p < 0.05), males, and those with moderate-to-severe disease. Among patients with congestive heart failure, IPF correlated strongly with D-dimer (r = 0.78, p = 0.013). Similar associations were observed in patients requiring enoxaparin or antiplatelet therapy. No significant correlations were found in patients age 70 or older. Based on these findings, we conclude that elevated IPF is associated with increased inflammatory and thrombotic activity in hospitalized COVID-19 patients, especially in younger, male, and more severe cases. These findings suggest IPF may serve as a dynamic marker for thrombo-inflammation and help identify patients who might benefit from more intensive antithrombotic therapy. Larger studies are warranted to validate IPF as a biomarker for personalized management of COVID-19.

1 October 2022
Verified
Journal Article
Closed access
ADAdrian Marcelo Duek
Adrian Marcelo Duek
ELEmmanuel Lellouche
Emmanuel Lellouche
SBSharon Ben Baruch
Sharon Ben Baruch
RMReut Mashiach
Reut Mashiach
YSYafit Segman
Yafit Segman
MLMerav Leiba
Merav Leiba

11 May 2024
Verified
Conference Paper
Closed access
OHOshrat Hershkovitz-Rokah
Oshrat Hershkovitz-Rokah
TZTal Zvida
Tal Zvida
EMEli Muchtar
Eli Muchtar
MSMali Salmon-Divon
Mali Salmon-Divon
ADAngela Dispenzieri
Angela Dispenzieri
OSOfer Shpilberg
Ofer Shpilberg
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER

1 July 2021
Verified
Journal Article
Closed access
ADAdrian Marcelo Duek
Adrian Marcelo Duek
BKBatia Kaplan
Batia Kaplan
YSYafit Segman
Yafit Segman
MLMerav Leiba
Merav Leiba